NCT04151706 CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML Status COMPLETED Phase PHASE2
NCT04095858 Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005) Status TERMINATED Phase PHASE3
NCT04093570 A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) Status ENROLLING_BY_INVITATION Phase PHASE2
NCT04060485 Screening Gene Mutations in Myeloid Cancers by Next Generation Sequencing to Improve Treatment Results Status UNKNOWN Phase N/A
NCT04055844 Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS Status COMPLETED Phase PHASE2
NCT04053933 Observational Study Towards the Impact of Newly Started Treatment in MDS on QoL Status COMPLETED Phase N/A
NCT04044209 A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS Status WITHDRAWN Phase PHASE2
NCT04036448 A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea Status COMPLETED Phase N/A
NCT04024761 A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation Status RECRUITING Phase PHASE1
NCT04014764 Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy Status COMPLETED Phase N/A
NCT04013685 Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT04003220 Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker Status UNKNOWN Phase N/A
NCT03964506 Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant Status RECRUITING Phase EARLY_PHASE1
NCT03961919 Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant Status COMPLETED Phase PHASE2
NCT03946670 A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS). Status TERMINATED Phase PHASE2
NCT03932643 ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant Status COMPLETED Phase PHASE1
NCT03929211 CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome Status WITHDRAWN Phase PHASE1/PHASE2
NCT03927261 PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT03920657 Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS Status TERMINATED Phase PHASE2